Abstract
A new series of Furan‐2‐carboxamide derivatives of anthraquinone (compounds N1, N3, N5) were synthesized and tested in vivo using Triton WR‐1339‐induced hyperlipidemic rat as an experimental model for their hypolipidemic activity. The tested animals were divided into six groups: control, hyperlipidemic, N1, N3, N5 and bezafibrate. The designed target derivatives, compounds N1, N3 were inactive. Compound N5 has shown a significant reduction in triglyceride level in rats by 66.5% after 18 h in comparison to the hyperlipidemic group. Furthermore, high‐density lipoprotein‐cholesterol levels were remarkably increased in compound N5 (p < 0.001) after 18 h in comparison to the hyperlipidemia group and also compound N5 significantly reduced LDL‐C level (p< 0.001) after 18 h in comparison to the hyperlipidemia group. Furthermore, the total cholesterol level was reduced by 85% after 18 h in compound N5 compared to HLG‐treated rats. The present study demonstrated new properties of novel series of furan‐2‐carboxamides N5 as a potent lipid‐lowering agent. It is therefore reasonable to assume that this compound may have a promising potential in the treatment of hyperlipidemia and coronary heart diseases.Grant Funding Source: This research is supported by Al‐Zaytoonah University of Jordan
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
